Laboratory Stakeholders Urge FDA To Ditch IVDMIA Guidance, Pursue Rule
This article was originally published in The Gray Sheet
Executive Summary
FDA should start over in its efforts to claim regulatory oversight of a new class of high-tech laboratory-developed tests through a guidance document and begin a formal rulemaking process, diagnostic industry stakeholders said at a Feb. 8 hearing